Investments (Tables)

12 Months Ended

Dec. 31, 2021

These below equity investments are included in investments on the consolidated balance sheets as of December 31, 2021 and 2020 (in thousands):


	2021		2020
ShiraTronics, Inc.	$	3,331	$	2,045
Noctrix Health, Inc.	3,159		1,359
ALung Technologies, Inc. (1)	3,000		3,000
Ceribell, Inc.	3,000		3,000
MD Start II (2)	1,135		1,227
Rainbow Medical Ltd.	1,111		1,201
Highlife S.A.S.	1,075		1,163
Respicardia Inc. (3)	—		17,706
	15,811		30,701
Equity method investment (4)	787		393
	$	16,598	$	31,094

(1)ALung Technologies, Inc. (“ALung”) is a privately held medical device company focused on creating advanced medical devices for treating respiratory failure. We have a loan outstanding to ALung with a carrying amount of $2.5 million and $2.5 million as of December 31, 2021 and 2020, respectively, which is included in prepaid expenses and other current assets on the consolidated balance sheet.

(2)During the second quarter of 2021 the Company received a cash dividend from its investment in MD Start II of $3.1 million, which is included in foreign exchange and other gains/(losses) on the consolidated statements of income (loss) for the year ended December 31, 2021.

(3)In April 2021, Zoll Medical Corporation acquired Respicardia Inc. As a result of the acquisition we received proceeds of $23.1 million for our investment and loan receivable with carrying values of $17.7 million and $0.8 million as of December 31, 2020, respectively. The Company recorded a gain of $4.6 million during the first quarter of 2021 to adjust the investment and loans receivable to fair value, which is included in foreign exchange and other gains/(losses) on the consolidated statements of income (loss) for the year ended December 31, 2021.

(4)We are required to fund follow-on investments up to a total of approximately €5.0 million (approximately $5.7 million as of December 31, 2021) based on cash calls.